Introduction
The international outbreak of respiratory illness termed coronavirus
disease 2019 (COVID-19) began in December 2019 and has affected millions
of individuals worlwide. There are various therapeutic agents approved
by FDA for COVID-19. For instance, favipiravir is reported as one of the
possible medications for shortening the duration of COVID-19 symptoms,
by reducing inflammation. Here, we report the case of a 57-year-old man
presented with fever and dry cough, who had COVID-19 infection and later
presented with erosions in oral, anogenital regions and dorsum of his
hands.